Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | MT-3724 |
Synonyms | |
Therapy Description |
MT-3724 is a cytotoxic antibody that targets CD20-expressing cells, which may block protein synthesis and induce apoptosis of tumor cells (PMID: 29559616). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
MT-3724 | MT3724 | CD20 Antibody 24 | MT-3724 is a cytotoxic antibody that targets CD20-expressing cells, which may block protein synthesis and induce apoptosis of tumor cells (PMID: 29559616). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02361346 | Phase Ib/II | MT-3724 | Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCL (MT-3724NHL001) | Terminated | USA | POL | ISR | ESP | CAN | 5 |
NCT02715843 | Expanded access | MT-3724 | Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma | No longer available | USA | 0 |